PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Status Recruiting

Clinical Trial Summary

Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tumors.

Clinical Trial Description

First-in-human, open-label, dose-finding, phase I trial, using a classical 3+3 design followed by a continual reassessment method (CRM). Patients will be included in cohorts of a minimum of three or six patients to receive PM14 at successively increasing dose levels, starting at 0.25 mg/m^2 for the Days 1 and 8 schedule. For the Day 1 schedule, the starting dose will be 4.5 mg/m^2. Dose escalation will proceed only after all the patients fully evaluable for DLT included at one dose level have completed the first cycle (i.e., three weeks). Once the RD has been determined, expansion cohorts will be included to have a minimum of 20 fully evaluable patients per indication (tumor type) treated in the Expansion phase (regardless of the schedule administered), and thus have an adequate number of patients to assess safety. The indications of these patients will be chosen depending on the efficacy data obtained during dose escalation. Patients treated at the expansion cohorts will be evaluable by the Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) and/or by serum markers only in patients with prostate cancer (prostate specific-antigen [PSA]) or ovarian cancer (carbohydrate antigen-125 [CA-125]) according to the Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and the Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05076396
Study type	Interventional
Source	PharmaMar
Contact	Carmen Kahatt, MD, PhD
Phone	0034 91 823 4615
Email	ckahatt@pharmamar.com
Status	Recruiting
Phase	Phase 1
Start date	September 6, 2017
Completion date	August 13, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06223308` - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT05508100` - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors	Phase 1
Not yet recruiting	`NCT05515185` - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors	Early Phase 1
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Completed	`NCT02836600` - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04890613` - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Phase 1
Recruiting	`NCT04390737` - Evaluate the Safety and Clinical Activity of HH2853	Phase 1/Phase 2
Recruiting	`NCT05981703` - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06007482` - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT04108676` - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects	Phase 1
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Recruiting	`NCT06054932` - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors	Phase 1
Recruiting	`NCT06008366` - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04825392` - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06365918` - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis	Phase 1
Recruiting	`NCT05443126` - A Study of EP0031 in Patients With Advanced RET-altered Malignancies	Phase 1/Phase 2
Recruiting	`NCT05461287` - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05569057` - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma	Phase 1
Active, not recruiting	`NCT04592653` - Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.